Literature DB >> 12721214

Effects of medical or surgical castration on erectile function in an animal model.

Abdulmaged M Traish1, Ricardo Munarriz, Luke O'Connell, Seong Choi, Soo Woong Kim, Noel N Kim, Yue-Hua Huang, Irwin Goldstein.   

Abstract

The goal of this study was to investigate the effects of medical castration (luteinizing hormone-receptor hormone [LH-RH] agonist treatment) or surgical castration on erectile function in an animal model. New Zealand White male rabbits were either kept intact (control); surgically orchiectomized; or treated for 2, 4, or 8 weeks with the LH-RH agonist leuprolide acetate (107 microg/kg/mo). At 2 weeks, plasma testosterone levels of orchiectomized and leuprolide acetate-treated animals were 12.8% and 57.4% of intact control animals, respectively. Erectile function was assessed by continuously recording systemic arterial pressure (SAP) and intracavernosal blood pressure (ICP) and determining the ICP:SAP ratios in response to electrical stimulation of the pelvic nerve at varying frequencies (2.5-32 Hz). Androgen deprivation by surgical (orchiectomy) or medical (leuprolide acetate) castration reduced ICP at all frequencies tested but did not alter SAP. Administration of the phosphodiesterase type 5 inhibitor vardenafil (10 microg/kg) did not enhance ICP in surgically orchiectomized or leuprolide acetate-treated animals. Nitric oxide synthase and arginase activities in the corpus cavernosum were not significantly altered by surgical or medical castration. Further, Masson trichrome staining of erectile tissue from androgen-ablated animals showed a reduction in smooth muscle content. These data demonstrate that androgen deprivation achieved by surgical or medical castration adversely affects penile hemodynamics and erectile function without producing significant changes in the activities of nitric oxide synthase or arginase. We conclude that androgen deprivation produces structural alterations in the corpus cavernosum leading to corporal veno-occlusive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721214     DOI: 10.1002/j.1939-4640.2003.tb02686.x

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  25 in total

Review 1.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

2.  Men's aging and sexual disorders: an update on diagnosis and treatment.

Authors:  Alvaro Morales
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 3.  Androgens are fundamental in the maintenance of male sexual health.

Authors:  Alvaro Morales
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 4.  Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction.

Authors:  Carol A Podlasek; John Mulhall; Kelvin Davies; Christopher J Wingard; Johanna L Hannan; Trinity J Bivalacqua; Biljana Musicki; Mohit Khera; Nestor F González-Cadavid; Arthur L Burnett
Journal:  J Sex Med       Date:  2016-08       Impact factor: 3.802

Review 5.  Molecular mechanisms associated with diabetic endothelial-erectile dysfunction.

Authors:  Ângela Castela; Carla Costa
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

6.  Treatment of erectile dysfunction in a hypogonadal male.

Authors:  John P Mulhall
Journal:  Rev Urol       Date:  2004

7.  The molecular basis of erectile dysfunction: from bench to bedside.

Authors:  Jesse N Mills; Albaha Barqawi; Sweaty Koul; Hari Koul; Randall B Meacham
Journal:  Rev Urol       Date:  2005

8.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

Review 9.  [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].

Authors:  L Rinnab; K Gust; R E Hautmann; R Küfer
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

Review 10.  Which patients with sexual dysfunction are suitable for testosterone replacement therapy?

Authors:  A Morelli; G Corona; S Filippi; S Ambrosini; G Forti; L Vignozzi; M Maggi
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.